Alpine Immune Sciences, Inc.
NASDAQ:ALPN
64.97 (USD) • At close May 17, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Alpine Immune Sciences, Inc. |
Symbool | ALPN |
Munteenheid | USD |
Prijs | 64.97 |
Beurswaarde | 4,456,779,835 |
Dividendpercentage | 0% |
52-weken bereik | 8.33 - 65 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mitchell H. Gold M.D. |
Website | https://www.alpineimmunesciences.com |
An error occurred while fetching data.
Over Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)